Jinhong Chang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5613314/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	4-Oxooctahydroquinoline-1(2H)-carboxamides as hepatitis B virus (HBV) capsid core protein assembly modulators. Bioorganic and Medicinal Chemistry Letters, 2022, 58, 128518.	1.0	3
2	A yellow fever virus NS4B inhibitor not only suppresses viral replication, but also enhances the virus activation of RIG-I-like receptor-mediated innate immune response. PLoS Pathogens, 2022, 18, e1010271.	2.1	9
3	Synthesis of 4-oxotetrahydropyrimidine-1(2H)-carboxamides derivatives as capsid assembly modulators of hepatitis B virus. Medicinal Chemistry Research, 2021, 30, 459-472.	1.1	6
4	Restoration of a functional antiviral immune response to chronic HBV infection by reducing viral antigen load: if not sufficient, is it necessary?. Emerging Microbes and Infections, 2021, 10, 1545-1554.	3.0	12
5	Hepatitis B virus nucleocapsid uncoating: biological consequences and regulation by cellular nucleases. Emerging Microbes and Infections, 2021, 10, 852-864.	3.0	16
6	A Putative Amphipathic Alpha Helix in Hepatitis B Virus Small Envelope Protein Plays a Critical Role in the Morphogenesis of Subviral Particles. Journal of Virology, 2021, 95, .	1.5	4
7	Identification of hepatitis B virus core protein residues critical for capsid assembly, pgRNA encapsidation and resistance to capsid assembly modulators. Antiviral Research, 2021, 191, 105080.	1.9	10
8	Amino acid residues at core protein dimer-dimer interface modulate multiple steps of hepatitis B virus replication and HBeAg biogenesis. PLoS Pathogens, 2021, 17, e1010057.	2.1	10
9	Development of antibody-based assays for high throughput discovery and mechanistic study of antiviral agents against yellow fever virus. Antiviral Research, 2020, 182, 104907.	1.9	4
10	Targeting the multifunctional HBV core protein as a potential cure for chronic hepatitis B. Antiviral Research, 2020, 182, 104917.	1.9	62
11	Protein phosphatase 1 catalyzes HBV core protein dephosphorylation and is co-packaged with viral pregenomic RNA into nucleocapsids. PLoS Pathogens, 2020, 16, e1008669.	2.1	26
12	A Sensitive Yellow Fever Virus Entry Reporter Identifies Valosin-Containing Protein (VCP/p97) as an Essential Host Factor for Flavivirus Uncoating. MBio, 2020, 11, .	1.8	24
13	Virological Basis for the Cure of Chronic Hepatitis B. ACS Infectious Diseases, 2019, 5, 659-674.	1.8	43
14	GILT restricts the cellular entry mediated by the envelope glycoproteins of SARS-CoV, Ebola virus and Lassa fever virus. Emerging Microbes and Infections, 2019, 8, 1511-1523.	3.0	26
15	Discovery and Mechanistic Study of a Novel Human-Stimulator-of-Interferon-Genes Agonist. ACS Infectious Diseases, 2019, 5, 1139-1149.	1.8	50
16	DNA Polymerase alpha is essential for intracellular amplification of hepatitis B virus covalently closed circular DNA. PLoS Pathogens, 2019, 15, e1007742.	2.1	59
17	Cellular DNA Topoisomerases Are Required for the Synthesis of Hepatitis B Virus Covalently Closed Circular DNA. Journal of Virology, 2019, 93, .	1.5	53
18	Discovery of Novel Hepatitis B Virus Nucleocapsid Assembly Inhibitors. ACS Infectious Diseases, 2019, 5, 759-768.	1.8	34

#	Article	IF	CITATIONS
19	Hepatitis B Virus Core Protein Dephosphorylation Occurs during Pregenomic RNA Encapsidation. Journal of Virology, 2018, 92, .	1.5	52
20	Enhancing the antiviral potency of ER α-glucosidase inhibitor IHVR-19029 against hemorrhagic fever viruses in vitro and in vivo. Antiviral Research, 2018, 150, 112-122.	1.9	26
21	In Vitro Anti-hepatitis B Virus Activity of 2′,3′-Dideoxyguanosine. Virologica Sinica, 2018, 33, 538-544.	1.2	2
22	CpAMs induce assembly of HBV capsids with altered electrophoresis mobility: Implications for mechanism of inhibiting pgRNA packaging. Antiviral Research, 2018, 159, 1-12.	1.9	17
23	Ester Prodrugs of IHVR-19029 with Enhanced Oral Exposure and Prevention of Gastrointestinal Glucosidase Interaction. ACS Medicinal Chemistry Letters, 2017, 8, 157-162.	1.3	14
24	Discovery and Mechanistic Study of Benzamide Derivatives That Modulate Hepatitis B Virus Capsid Assembly. Journal of Virology, 2017, 91, .	1.5	39
25	A cell-based high throughput screening assay for the discovery of cGAS-STING pathway agonists. Antiviral Research, 2017, 147, 37-46.	1.9	55
26	Activation of Stimulator of Interferon Genes in Hepatocytes Suppresses the Replication of Hepatitis B Virus. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	60
27	The current status and future directions of hepatitis B antiviral drug discovery. Expert Opinion on Drug Discovery, 2017, 12, 5-15.	2.5	44
28	HBV core protein allosteric modulators differentially alter cccDNA biosynthesis from de novo infection and intracellular amplification pathways. PLoS Pathogens, 2017, 13, e1006658.	2.1	105
29	Characterization of novel hepadnaviral RNA species accumulated in hepatoma cells treated with viral DNA polymerase inhibitors. Antiviral Research, 2016, 131, 40-48.	1.9	22
30	A Novel Benzodiazepine Compound Inhibits Yellow Fever Virus Infection by Specifically Targeting NS4B Protein. Journal of Virology, 2016, 90, 10774-10788.	1.5	37
31	Article Commentary: Viral Resistance of MOGS-CDG Patients Implies a Broad-Spectrum Strategy against Acute Virus Infections. Antiviral Therapy, 2015, 20, 257-259.	0.6	19
32	Inhibition of Endoplasmic Reticulum-Resident Glucosidases Impairs Severe Acute Respiratory Syndrome Coronavirus and Human Coronavirus NL63 Spike Protein-Mediated Entry by Altering the Glycan Processing of Angiotensin I-Converting Enzyme 2. Antimicrobial Agents and Chemotherapy, 2015, 59, 206-216	1.4	63
33	Treatment of chronic hepatitis B with pattern recognition receptor agonists: Current status and potential for a cure. Antiviral Research, 2015, 121, 152-159.	1.9	45
34	STING Agonists Induce an Innate Antiviral Immune Response against Hepatitis B Virus. Antimicrobial Agents and Chemotherapy, 2015, 59, 1273-1281.	1.4	93
35	Interferon induction of IFITM proteins promotes infection by human coronavirus OC43. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 6756-6761.	3.3	161
36	Therapeutic strategies for a functional cure of chronic hepatitis B virus infection. Acta Pharmaceutica Sinica B, 2014, 4, 248-257.	5.7	48

#	Article	IF	CITATIONS
37	An interferon-beta promoter reporter assay for high throughput identification of compounds against multiple RNA viruses. Antiviral Research, 2014, 107, 56-65.	1.9	18
38	Antiviral therapies targeting host ER alpha-glucosidases: Current status and future directions. Antiviral Research, 2013, 99, 251-260.	1.9	98
39	N-Alkyldeoxynojirimycin derivatives with novel terminal tertiary amide substitution for treatment of bovine viral diarrhea virus (BVDV), Dengue, and Tacaribe virus infections. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 2172-2176.	1.0	12
40	Small molecule inhibitors of ER α-glucosidases are active against multiple hemorrhagic fever viruses. Antiviral Research, 2013, 98, 432-440.	1.9	72
41	Design and synthesis of N-alkyldeoxynojirimycin derivatives with improved metabolic stability as inhibitors of BVDV and Tacaribe virus. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 4258-4262.	1.0	10
42	Alpha-Interferon Suppresses Hepadnavirus Transcription by Altering Epigenetic Modification of cccDNA Minichromosomes. PLoS Pathogens, 2013, 9, e1003613.	2.1	135
43	Sulfamoylbenzamide Derivatives Inhibit the Assembly of Hepatitis B Virus Nucleocapsids. Journal of Virology, 2013, 87, 6931-6942.	1.5	154
44	lmino sugar glucosidase inhibitors as broadly active anti-filovirus agents. Emerging Microbes and Infections, 2013, 2, 1-7.	3.0	21
45	Design, Synthesis, and Biological Evaluation of <i>N</i> -Alkylated Deoxynojirimycin (DNJ) Derivatives for the Treatment of Dengue Virus Infection. Journal of Medicinal Chemistry, 2012, 55, 6061-6075.	2.9	49
46	PD 404,182 Is a Virocidal Small Molecule That Disrupts Hepatitis C Virus and Human Immunodeficiency Virus. Antimicrobial Agents and Chemotherapy, 2012, 56, 672-681.	1.4	35
47	The innate immune response to hepatitis B virus infection: Implications for pathogenesis and therapy. Antiviral Research, 2012, 96, 405-413.	1.9	58
48	RO 90-7501 Enhances TLR3 and RLR Agonist Induced Antiviral Response. PLoS ONE, 2012, 7, e42583.	1.1	19
49	Combination of α-glucosidase inhibitor and ribavirin for the treatment of dengue virus infection in vitro and in vivo. Antiviral Research, 2011, 89, 26-34.	1.9	83
50	Competitive inhibitor of cellular α-glucosidases protects mice from lethal dengue virus infection. Antiviral Research, 2011, 92, 369-371.	1.9	38
51	Inhibitors of Endoplasmic Reticulum α-Glucosidases Potently Suppress Hepatitis C Virus Virion Assembly and Release. Antimicrobial Agents and Chemotherapy, 2011, 55, 1036-1044.	1.4	58
52	Alkylated Porphyrins Have Broad Antiviral Activity against Hepadnaviruses, Flaviviruses, Filoviruses, and Arenaviruses. Antimicrobial Agents and Chemotherapy, 2011, 55, 478-486.	1.4	52
53	Interferons Accelerate Decay of Replication-Competent Nucleocapsids of Hepatitis B Virus. Journal of Virology, 2010, 84, 9332-9340.	1.5	114
54	Interferon-Induced Cell Membrane Proteins, IFITM3 and Tetherin, Inhibit Vesicular Stomatitis Virus Infection via Distinct Mechanisms. Journal of Virology, 2010, 84, 12646-12657.	1.5	263

#	Article	IF	CITATIONS
55	Identification of Five Interferon-Induced Cellular Proteins That Inhibit West Nile Virus and Dengue Virus Infections. Journal of Virology, 2010, 84, 8332-8341.	1.5	292
56	Activation of Pattern Recognition Receptor-Mediated Innate Immunity Inhibits the Replication of Hepatitis B Virus in Human Hepatocyte-Derived Cells. Journal of Virology, 2009, 83, 847-858.	1.5	108
57	Antiviral effect of interferon lambda against West Nile virus. Antiviral Research, 2009, 83, 53-60.	1.9	45
58	Novel Imino Sugar Derivatives Demonstrate Potent Antiviral Activity against Flaviviruses. Antimicrobial Agents and Chemotherapy, 2009, 53, 1501-1508.	1.4	74
59	Liver-Specific MicroRNA miR-122 Enhances the Replication of Hepatitis C Virus in Nonhepatic Cells. Journal of Virology, 2008, 82, 8215-8223.	1.5	214
60	Transcription of Hepatitis Delta Virus RNA by RNA Polymerase II. Journal of Virology, 2008, 82, 1118-1127.	1.5	92
61	Identification of Three Interferon-Inducible Cellular Enzymes That Inhibit the Replication of Hepatitis C Virus. Journal of Virology, 2008, 82, 1665-1678.	1.5	255
62	Assembly of Hepatitis B Virus Envelope Proteins onto a Lentivirus Pseudotype That Infects Primary Human Hepatocytes. Journal of Virology, 2007, 81, 10897-10904.	1.5	25
63	Assembly of Hepatitis Delta Virus: Particle Characterization, Including the Ability To Infect Primary Human Hepatocytes. Journal of Virology, 2007, 81, 3608-3617.	1.5	56
64	Immunoadhesins Containing Pre-S Domains of Hepatitis B Virus Large Envelope Protein Are Secreted and Inhibit Virus Infection. Journal of Virology, 2007, 81, 4912-4918.	1.5	11
65	Restoration in vivo of defective hepatitis delta virus RNA genomes. Rna, 2006, 12, 1061-1073.	1.6	6
66	Action of Inhibitors on Accumulation of Processed Hepatitis Delta Virus RNAs. Journal of Virology, 2006, 80, 3205-3214.	1.5	26
67	Development of a Novel System To Study Hepatitis Delta Virus Genome Replication. Journal of Virology, 2005, 79, 8182-8188.	1.5	57
68	Reconstitution in cultured cells of replicating HDV RNA from pairs of less than full-length RNAs. Rna, 2005, 11, 90-98.	1.6	24
69	Evolution of Hepatitis Delta Virus RNA Genome following Long-Term Replication in Cell Culture. Journal of Virology, 2005, 79, 13310-13316.	1.5	25
70	Alternative Processing of Hepatitis Delta Virus Antigenomic RNA Transcripts. Journal of Virology, 2004, 78, 4517-4524.	1.5	22
71	miR-122, a Mammalian Liver-Specific microRNA, is Processed from hcr mRNA and MayDownregulate the High Affinity Cationic Amino Acid Transporter CAT-1. RNA Biology, 2004, 1, 106-113.	1.5	758
72	Features Affecting the Ability of Hepatitis Delta Virus RNAs To Initiate RNA-Directed RNA Synthesis. Journal of Virology, 2004, 78, 5737-5744.	1.5	18

#	Article	IF	CITATIONS
73	Resistance of Human Hepatitis Delta Virus RNAs to Dicer Activity. Journal of Virology, 2003, 77, 11910-11917.	1.5	57
74	Susceptibility of Human Hepatitis Delta Virus RNAs to Small Interfering RNA Action. Journal of Virology, 2003, 77, 9728-9731.	1.5	60
75	Parameters of Human Hepatitis Delta Virus Genome Replication: the Quantity, Quality, and Intracellular Distribution of Viral Proteins and RNA. Journal of Virology, 2002, 76, 3709-3719.	1.5	90
76	In vivo RNA-directed transcription, with template switching, by a mammalian RNA polymerase. EMBO Journal, 2002, 21, 157-164.	3.5	54
77	Replication of the Human Hepatitis Delta Virus Genome Is Initiated in Mouse Hepatocytes following Intravenous Injection of Naked DNA or RNA Sequences. Journal of Virology, 2001, 75, 3469-3473.	1.5	80
78	Interactions between Hepatitis Delta Virus Proteins. Journal of Virology, 2000, 74, 5509-5515.	1.5	17
79	Limitations to Replication of Hepatitis Delta Virus in Avian Cells. Journal of Virology, 2000, 74, 8861-8866.	1.5	15
80	Efficient Site-Specific Nonribozyme Opening of Hepatitis Delta Virus Genomic RNA in Infected Livers. Journal of Virology, 2000, 74, 9889-9894.	1.5	9
81	Relationship between interferon therapy and variability in nonstructural gene 5b of hepatitis C virus. Journal of Gastroenterology, 1998, 33, 684-693.	2.3	6